Pharma Pricing and Market Access 2019 Day 2

Oliver Leatham
09:20

Innovative Solutions for Fast-Track Approvals

Panel discussion
10:20

Morning Refreshments

Nicki Catterick-Kang
11:00

Roundtables

PRICING & MARKET ACCESS

RARE DISEASES

AFFORDABILITY

ADVANCED THERAPIES

MANAGED ENTRY AGREEMENTS

EVIDENCE

AFFORDABILITY
12:05

Pharmaceutical Affordability

  • Ability to Pay versus Willingness to Pay
  • Considerations for Product-specific and Patient-specific affordability programs
  • Partnering with payers/policy makers
EVIDENCE
12:05

Federated & Harmonised Real World Research in the EU 2020+: A Convergence of Intent, Collaboration & Technology?

  • The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
  • Data harmonisation – an international initiative and the Rosetta Stone of RWD?
  • What have we learned from IMI EMIF, from its original inception, project experience, and sustainability scale up
  • The premise for EHDN, aims and likely impact
  • Meeting the needs of multiple stakeholders
ADVANCED THERAPIES
12:25

Health Economic Modelling in Gene Therapies

Gene therapies raise new challenges when it comes to developing models for use in health technology assessment (HTA), burden of illness and value demonstration. Tried-and-true methods pose special issues, as applied to genetic interventions. This session is a discussion of potential approaches to modeling for gene therapies, and the advantages and disadvantages of various modeling approaches as applied to these interventions.
ADVANCED THERAPIES
12:45

Access considerations in the world advanced therapies

  • CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
  • Drug or therapeutic method: first experiences in the German health care system
  • Most expensive cancer treatment ever: New approaches for affordability and sustainability
13:05

Networking Lunch

PRICING & MARKET ACCESS

RARE DISEASES

CONTRACTING AND PRICE TENDERING

ADVANCED THERAPIES

PATIENT AND PAYER ENGAGEMENT

EVIDENCE

EVIDENCE
14:10

Precision medicine in oncology: challenges and possible solutions from a payer’s perspective

  • What are the key challenges we face in commissioning tests and treatments in this fast-paced and innovative field?
  • How can we ensure our patients have access to tests and treatments that are safe and effective despite limited evidence?
  • What solutions could be considered to manage costs to payers (and our customers) and safeguard precision medicine as a sustainable option in the future?
PRICING AND MARKET ACCESS
14:30

Quantifying the ‘patient voice’: the importance of tolerability and quality-of-survival in HTA decisions

  • HTA and payer-relevant quantitative concepts to characterize AE profiles and tolerability will be reviewed
  • HTA acceptance of these quant. approaches will be illustrated and appraised
  • Examples and (potential future) approaches, for HTA and Access success will be discussed
15:10

Afternoon Refreshments

PRICING & MARKET ACCESS

RARE DISEASES

MEDCIAL AND GOVERNMENTAL AFFAIRS

ADVANCED THERAPIES

EVIDENCE

ADVANCED THERAPIES
15:45

Examining the regulatory landscape for CAR-T

  • CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
  • Drug or therapeutic method: first experiences in the German health care system
  • Most expensive cancer treatment ever: New approaches for affordability and sustainability
PRICING AND MARKET ACCESS
16:25

HTA in Switzerland

  • Legal Context of HTA in Switzerland
  • HTA Processes
  • Implementation of HTA
last published: 05/Apr/19 15:27 GMT